PRESS

Cardiogen GmbH, a preclinical life-science company focused on cardiovascular regeneration and cellular reprogramming, today announced the successful completion of its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead program, CGN001, being developed for the treatment of ST-elevation myocardial infarction (STEMI).

Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and cellular reprogramming, is attending the annual J.P. Morgan Healthcare Conference in San Francisco.

Cardiogen GmbH, a preclinical life science company focusing on cardiovascular regeneration and cellular reprogramming, announced that the Pre-IND meeting with the first National Regulatory Agency in Europe was completed successfully and positive feedback on the planned pre- and clinical development program for CGN001 in ST-elevation myocardial infarction was received.